Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pfizer (NY:PFE)

24.49 +0.20 (+0.84%)
Streaming Delayed Price Updated: 12:51 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Drug Prices To Get 'More Expensive' Under Trump's EU Trade Deal As Pharma Faces Billions In Added Costs: Report
The pharmaceutical industry could face a significant financial hit due to the new trade deal between the U.S. and the European Union (EU), potentially leading to increased drug prices and restricted... 
Via Benzinga
Topics Government
Robert Kennedy Jr Blasts Vaccine Injury Compensation Program: 'Devolved Into A Morass Of Inefficiency, Favoritism, And Outright Corruption'
Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. is pledging a major overhaul of the National Vaccine Injury Compensation Program (VICP), describing the system as fundamentally broken... 
Via Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
These big pharma stocks arguably aren't receiving the respect they deserve. 
Via The Motley Fool
Topics Intellectual Property
Palantir, Nvidia & Tempus AI Could Be Pharma ETF Darlings That Don't Make Pills
Sci-fi becomes reality: AI-native pharma disruptors like Palantir, Tempus, and Recursion are reshaping medicine. But ETFs still favor old-school giants. 
Via Benzinga
Topics Artificial Intelligence ETFs
Bristol Myers, Pfizer To Offer Blood Thinning Drug At Discount: Retail Chatter Around BMY Jump 60% In 24 Hours
Via Stocktwits
How Palantir, Tempus, Nvidia-Backed Recursion Are Disrupting Big Pharma
AI-native players like Palantir, Tempus, and Recursion are disrupting drug discovery and attracting investors, while Big Pharma struggles. 
Via Benzinga
Warren Buffett Owns 10 High-Yield Dividend Stocks. Here's the Best of the Bunch.
Via The Motley Fool
Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
Zoetis (ZTS): Buy, Sell, or Hold Post Q1 Earnings?
Over the last six months, Zoetis’s shares have sunk to $153.39, producing a disappointing 11.4% loss - a stark contrast to the S&P 500’s 5.8% gain. This may have investors wondering how to approach the... 
Via StockStory
Topics Government Stocks World Trade
Jim Cramer Praises Lowe's CEO, As For CrowdStrike: 'I'll See You At $1000'
On CNBC's "Mad Money Lightning Round," Jim Cramer praised home improvement retailer Lowe's Companies and CrowdStrike Holdings. 
Via Benzinga
Pfizer’s ‘Depo-Provera’ Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits
From Levin Papantonio
Via GlobeNewswire
Pfizer Completes Licensing Agreement with 3SBio
From Pfizer Inc.
Via Business Wire
Winners And Losers Of Q1: Zoetis (NYSE:ZTS) Vs The Rest Of The Branded Pharmaceuticals Stocks
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Zoetis (NYSE:ZTS) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Q1 Earnings Recap: Bristol-Myers Squibb (NYSE:BMY) Tops Branded Pharmaceuticals Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound
The entire healthcare sector has fallen into a deeply discounted valuation, creating opportunities for investors who hunt for value and upside 
Via MarketBeat
Topics Artificial Intelligence
Abivax Hits The Stratosphere, Up 500%, On 'Potentially Disruptive' Results
The results represent a best-case scenario for the company in treating inflammatory bowel disease, according to one analyst. 
Via Investor's Business Daily
1 Mid-Cap Stock on Our Buy List and 2 We Avoid
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
2 Undervalued Healthcare Stocks Poised to Dominate the Next Decade
Via The Motley Fool
Topics Intellectual Property
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
 
Via Benzinga
Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead?
Via The Motley Fool
Topics Economy Intellectual Property
5 High-Yield Stock Picks to Add to Your Dividend Portfolio
It might be prudent to make a point of collecting a little more cash in the near future, and worry a little less about growth. 
Via The Motley Fool
2 Reliable Dividend Stocks With Yields Above 6% That You Can Buy With $100 Right Now
Via The Motley Fool
Topics Retirement
Bristol‑Myers Squibb, Pfizer Set To Launch Direct‑To‑Patient Eliquis At 40% Off
Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and nationwide delivery. 
Via Benzinga
Which S&P500 stocks are the most active on Thursday?
Curious about the most active S&P500 stocks in today's session? Join us as we explore the US markets on Thursday and uncover the stocks that are leading the way in terms of trading volume and market... 
Via Chartmill
1 Cash-Producing Stock with Competitive Advantages and 2 to Avoid
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak... 
Via StockStory
Q1 Earnings Highs And Lows: Viatris (NASDAQ:VTRS) Vs The Rest Of The Generic Pharmaceuticals Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how generic pharmaceuticals stocks fared in Q1, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback
Via The Motley Fool
Don’t Miss These 4 Stocks With Explosive Dividend Yields
Via MarketBeat
Topics Stocks
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations. 
Via Benzinga
Topics Intellectual Property
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.